Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Braz. j. med. biol. res ; 53(6): e9275, 2020. tab, graf
Article in English | LILACS, ColecionaSUS | ID: biblio-1132525

ABSTRACT

Evidence from previous voxel-based morphometry (VBM) studies indicates that widespread brain regions are involved in Parkinson's disease with mild cognitive impairment (PD-MCI). However, the spatial localization reported for gray matter (GM) abnormalities is heterogeneous. The aim of the present study was to quantitatively integrate studies on GM abnormalities observed in PD-MCI in order to determine whether a pattern exists. Eligible whole-brain VBM studies were identified by a systematic search of articles in PubMed and EMBASE databases spanning from 1995 to January 1, 2019. A meta-analysis was performed to investigate regional GM abnormalities in PD-MCI. The anisotropic effect size version of seed-based d mapping (AES-SDM) meta-analysis was conducted to explore the GMV differences of PD-MCI compared with PD patients with normal cognitive function (PD-NC). A total of 12 studies comprising 243 PD-MCI patients and 326 PD-NC were included in the meta-analysis. PD-MCI patients showed a robust GM decrease in the left insula and left superior temporal gyrus. Moreover, meta-regression analysis demonstrated that age, PD duration and stage, and Unified Parkinson's Disease Rating Scale III and Mini-Mental State Examination scores might be partly correlated with the GM abnormalities observed in PD-MCI patients. The convergent findings of this quantitative meta-analysis revealed a characteristic neuroanatomical pattern in PD-MCI. The findings provide some evidence that MCI in PD may result in the breakdown of the insula and temporal gyrus, which may serve as specific regions of interest for further investigations.


Subject(s)
Humans , Male , Female , Middle Aged , Parkinson Disease/diagnostic imaging , Cognitive Dysfunction/diagnostic imaging , Gray Matter/diagnostic imaging , Parkinson Disease/physiopathology , Magnetic Resonance Imaging , Cognitive Dysfunction/physiopathology , Gray Matter/physiopathology , Gray Matter/pathology
2.
Braz. j. med. biol. res ; 51(7): e7218, 2018. tab, graf
Article in English | LILACS | ID: biblio-889121

ABSTRACT

The aim of this study was to investigate the efficacy, acceptability, and tolerability of antidepressants in treating post-stroke depression (PSD) by performing a network meta-analysis of randomized controlled trials of the current literature. Eligible studies were retrieved from online databases, and relevant data were extracted. The primary outcome was efficacy as measured by the mean change in overall depressive symptoms. Secondary outcomes included discontinued treatment for any reason and specifically due to adverse events. Fourteen trials were eligible, which included 949 participants and 9 antidepressant treatments. Few significant differences were found for all outcomes. For the primary outcome, doxepin, paroxetine, and nortriptyline were significantly more effective than a placebo [standardized mean differences: −1.93 (95%CI=−3.56 to −0.29), −1.39 (95%CI=−2.59 to −0.21), and −1.25 (95%CI=−2.46 to −0.04), respectively]. Insufficient evidence exists to select a preferred antidepressant for treating patients with post-stroke depression, and our study provides little evidence that paroxetine may be the potential choice when starting treatment for PSD. Future studies with paroxetine and larger sample sizes, multiple medical centers, and sufficient intervention durations is needed for improving the current evidence.


Subject(s)
Humans , Male , Female , Antidepressive Agents/therapeutic use , Depressive Disorder/drug therapy , Depressive Disorder/etiology , Stroke/complications , Network Meta-Analysis , Placebo Effect , Randomized Controlled Trials as Topic , Reproducibility of Results , Stroke/psychology , Time Factors , Treatment Outcome
3.
Braz. j. med. biol. res ; 49(6): e4806, 2016. tab, graf
Article in English | LILACS | ID: biblio-951682

ABSTRACT

New generation antidepressant therapies, including serotonin-norepinephrine reuptake inhibitor (SNRIs), were introduced in the late 1980s; however, few comprehensive studies have compared the benefits and risks of various contemporary treatments for major depressive disorder (MDD) in young patients. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science, and PsycINFO databases was conducted from 1970 to January 2015. Only clinical trials that randomly assigned one SNRI or placebo to patients aged 7 to 18 years who met the diagnostic criteria for major depressive disorder were included. Treatment success, dropout rate, and suicidal ideation/attempt outcomes were measured. Primary efficacy was determined by pooling the risk ratios (RRs) of treatment response and remission. Acceptability was determined by pooling the RRs of dropouts for all reasons and for adverse effects as well as suicide-risk outcomes. Five trials with a total of 973 patients were included. SNRIs were not significantly more effective than placebo for treatment response but were for remission. The comparison of patients taking SNRIs that dropped out for all reasons and those taking placebo did not reach statistical significance. Significantly more patients taking SNRIs dropped out for adverse effects than those taking placebo. No significant difference was found in suicide-related risk outcomes. SNRI therapy does not display a superior efficacy and is not better tolerated compared to placebo in these young patients. However, duloxetine has a potential beneficial effect for depression in young populations, showing a need for further research.


Subject(s)
Humans , Male , Female , Child , Adolescent , Randomized Controlled Trials as Topic , Depressive Disorder, Major/drug therapy , Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use , Antidepressive Agents/therapeutic use , Placebos/therapeutic use , Cyclopropanes/therapeutic use , Desvenlafaxine Succinate/therapeutic use , Duloxetine Hydrochloride/therapeutic use , Milnacipran
4.
Braz. j. med. biol. res ; 48(3): 198-206, 03/2015. tab, graf
Article in English | LILACS | ID: lil-741249

ABSTRACT

There has been concern regarding the use of controversial paradigms for repetitive transcranial magnetic stimulation (rTMS) to manage treatment-resistant depression (TRD). This meta-analysis assessed the efficacy of bilateral rTMS compared with unilateral and sham rTMS in patients with TRD. PubMed, Embase, CENTRAL, PsycINFO, Web of Science, EAGLE and NTIS databases were searched to identify relevant studies, and randomized controlled trials (RCTs) on bilateral rTMS for TRD patients were included. The response was defined as the primary outcome, and remission was the secondary outcome. Ten RCTs that included 634 patients met the eligibility criteria. The risk ratio (RRs) of both the primary and secondary outcomes of bilateral rTMS showed non-significant increases compared to unilateral rTMS (RR=1.01, P=0.93; odds ratio [OR]=0.77, P=0.22). Notably, the RR of the primary bilateral rTMS outcome was significantly increased compared to that for sham rTMS (RR=3.43, P=0.0004). The results of our analysis demonstrated that bilateral rTMS was significantly more effective than sham rTMS but not unilateral rTMS in patients with TRD. Thus, bilateral rTMS may not be a useful paradigm for patients with TRD.


Subject(s)
Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Environmental Exposure , Phthalic Acids/urine , Biomarkers/urine , Canada , Predictive Value of Tests , Respiratory Function Tests , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL